You're signed outSign in or to get full access.
About
David Xiang, MD MPH, is an Associate at Avoro Capital in New York, where he is responsible for evaluating and supporting investments in the biotechnology sector. He specializes in identifying and analyzing opportunities in innovative biotech companies, leveraging his advanced scientific and clinical background to inform the firm’s investment strategies.
Prior to joining Avoro Capital in 2025, David conducted research at Massachusetts General Hospital and interned at Blue Cross Blue Shield of Massachusetts, experiences that provided him with a strong foundation in healthcare systems and translational medicine. During medical school, he distinguished himself as a prolific researcher, with over 20 first-author publications in leading medical journals and additional contributions as a Doximity OpMed Fellow.
David holds an MD from Harvard Medical School, an MPH in Health Management from the Harvard T.H. Chan School of Public Health, and a BA in History & Science (Molecular and Cellular Biology) from Harvard College, graduating magna cum laude. His expertise integrates clinical medicine, public health, and investment analysis, providing Avoro Capital with a unique perspective on biotechnology investment opportunities and healthcare innovation.
Career History
| Organization | Role | Date Range | Details |
|---|---|---|---|
| Avoro Capital | Associate | Mar 2025 to Present | — |
| Massachusetts General Hospital | Research | Aug 2020 to May 2025 | 40+ peer-reviewed publications (20+ first author) in leading medical journals (JAAD, Communications Biology, JAMA Ophthalmology, Archives of Dermatological Research, etc) |
| Blue Cross Blue Shield of Massachusetts | Research Intern | Nov 2023 to May 2024 | Conducted claims-based research in the Performance Measures and Improvement Division |
| Doximity | Op-Med Fellow | Aug 2022 to Aug 2023 | Writing Profile: https://opmed.doximity.com/authors/david-xiang |
| New America | Health Policy Intern | May 2018 to Jul 2019 | — |
| Prolepsis Institute | Health Policy Intern | May 2017 to Jul 2017 | — |
| President's Committee on the Arts and the Humanities | National Student Poet | Oct 2015 to Oct 2016 | The nation's highest honor for youth poets presenting original work. Taught poetry workshops to underserved communities in the arts across the United States. Readings at the White House (hosted by for... |
| Research Science Institute (RSI) | Student Researcher at RSI (Research Science Institute) | Jun 2015 to Aug 2015 | Conducted original research at the Cardiac Muscle Research Laboratory at HMS, regarding the role of mitochondrial ubiquitin ligase activator of Nf-kB (Mulan) in cardiomyocytes. |
| UAMS - University of Arkansas for Medical Sciences | Student Researcher | May 2013 to Dec 2014 | Conducted original research regarding the effectiveness of siRNA transfections on oxidized lipoproteins (oxLDL) and one of its primary receptors, LOX-1. |
Education
Harvard Medical School
Doctor of Medicine - MD
2020 — 2025
Harvard T.H. Chan School of Public Health
Master of Public Health - MPH, Health Management
2023 — 2025
Harvard University
Bachelor’s Degree, History and Science, Molecular and Cellular Biology
Little Rock Central High School
High School
Skills & Expertise
Others at Avoro Capital Advisors LLC (6)
| Name | Role | Location |
|---|---|---|
 | Managing Partner | New York, NY , United States |
 | Partner | New York, NY , United States |
 | Trader | New York, NY , United States |
 | Senior Analyst | New York, NY , United States |
 | Analyst | New York, NY , United States |
S Stela Sota | Associate | New York, NY , United States |
Similar Fund Managers
| Name | Role | Fund | Location |
|---|---|---|---|
A Andrey Belov | Research Analyst | Cramer Rosenthal Mcglynn LLC | Stamford, CT , United States |
B Brian Harvey | Equity Portfolio Manager | Cramer Rosenthal Mcglynn LLC | United States |
